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Summary A retrospective analysis was made of the nature and composition of 107 con­
secutive topics presented in publications by or in collaboration with the national 
pharmacovigilance centre in The Netherlands, containing data obtained through 
‘spontaneous reporting’. These topics were published in various national and 
international professional journals or special bulletins or as ‘dear doctor letters’. 
The topics constituted a wide variety of events and disorders. There was, however, 
a predominance of concrete, characteristic and often serious diseases, notably 
specific hypersensitivity reactions (43%, e.g. anaphylaxis, blood dyscrasias and 
liver injury), toxic manifestations or syndromes (30%, especially involving the 
nervous system), and drug interactions (13%). Most topics presented predomi­
nantly qualitative information. 62% of topics concerned type B, 33% type A and 
3% type C adverse drug effects. The topics often referred to small numbers of 
case reports: 10 or less in 70% of the 107 topics. 46% of the topics concerned 
new i nformation. There was some predominance of established (56%) over new 
drugs. Five pharmacotherapeutic groups accounted for 74%» of topics. Of the 72 
approved drugs or drug groups, 12 (17%) have been removed from the market. 
These findings increase our understanding of the functioning of pharmaeo- 
ance and may enable further improvement of the methods and strategies 
involved.
Spontaneous reporting (i.e. the countrywide period o f relative stability and consolidation of
I re- procedures. During these years, the first author of• sus
actions, currently often referred to as pharmaco- this paper was director of the centre.
vigilance) was first started in The Netherlands in The major aims of pharmacovigilance are the
1963.1'1 The first 10 years o f The Netherlands early detection of new adverse effects, identifica-
national pharmacovigilance centre (Pharmaceuti- tion of risk factors and mechanisms, quantitative
cal Inspection, Ministry o f Health) were charac- risk assessment, and analysis and dissemination of
terisedby experimentation and change. During that information. Pharmacovigilance is still under
period results of the system were only rarely used 
publicly. The next 18 years (1973 to 1990) were a needed.
improvements may
We retrospectively analysed the nature and 
composition of the topics addressed during the 
period 1973 to 1990 in publications by or in colla­
boration with the pharmacovigilance centre in 
The Netherlands, containing data from original 
case reports. The purpose was to find out whether 
certain characteristics and patterns can be recog­
nised that may be o f value for further improve­
ments in pharmacovigilance. The contributions of 
pharmacovigilance to the drug regulatory authority 
(the Medicines Evaluation Board), e.g. changes in 
the product information sheets or withdrawals, 
were not studied because of the secrecy observed 
by this Board.
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5. Unexpected therapeutic effects
Materials and Methods
Fig. 1. Topics in pharmacovigilance.
Methods
The pharmacovigilance system in The Nether­
lands is based on countrywide ‘spontaneous report­
ing’ by physicians and, less frequently, by pharma­
cists and dentists o f cases of suspected adverse 
drug effects.1 All published information that had 
been issued by or in collaboration with The Neth­
erlands national pharmacovigilance centre was
collected during the period 1973 to 1990, e.g. in 
professional bulletins or journals or as ‘dear doctor 
letters’. These communications were screened for 
the presence of topics (i.e. information concerning
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(e.g. anaphylaxis, hepatitis,
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2. Manifestations of drug toxicity (e.g. organ toxicity,
effects, embryotoxicity)
Fig. 2. Classification of drug-induced diseases and syndromes.
Classification of Adverse Effects
Adverse effects were classified according to
a specific adverse event or other problem in rela- established categories: type A, B and C effects.!2 4!
tion to one or more drugs) referring to case re- Type A effects ( ‘drug actions’) are those resulting
ports received through spontaneous reporting, from exaggerated pharmacological actions or from
with or without data from other sources. interactions between drugs. Type A effects tend to
Drug-related events and problems are extremely be fairly common, and may
varied, ranging from simple complaints or abnor avoided by using doses that are appropriate to the
mal laboratory values to full-blown and serious individual patient. Such effects can usually be re­
diseases. In order to identify characteristics and produced and studied experimentally, and are often 
patterns, the topics were grouped using a classi- already identified before marketing.
fication based on event nature, clinicopathological Type B effects ( ‘patient reactions’) charae-
and pharmacological determinants, and rele- teristically occur only in a minority of patients and
vanee, as shown in figures 1 and 2. include immunoallergic and ‘idiosyncratic’ reac-
The various drug-induced diseases and syn- tions, and intolerance due to abnormal metabolism.
dromes (item 2.3) were subdivided as in figure 2. Type B may little or no dose
co Adis International Limited. All rights reserved. Clin. Drug Invest, 1996 Oct; 12 (4)
relationship, but often there is a suggestive time 
relationship between drug intake and onset and 
course. They generally are unpredictable, may be 
serious, and are notoriously difficult to study 
experimentally.
Type C effects refer to situations where the use 
of a drug may (often for unknown reasons) in­
crease the frequency of a ‘spontaneous’ disease. 
Type C effects may be both serious and relatively 
common (and include malignant tumours), and 
may have pronounced effects on public health. 
These events may be coincidental and frequently
• Type of adverse effect
• 'Age' of suspected drug
i
• New topic?
• Number of case reports Involved
• Source of case reports (national or international)
• Withdrawal from the market?
Fig. 3. Further pharmacovigilance topics assessment items.
involve long term effects; there often is no sugges­
tive time relationship and the connection may be
very difficult to prove.
Classification According to Group and ‘Age’
ered new (unless the topic appeared as a reaction 
to the earlier report). When a topic was addressed 
for a second time it was no longer considered new.
The suspected drugs in the topics were classi- The topics were studied in a quantitative way by 
fied according to pharmacotherapeutic group and counting the numbers of case reports involved, 
‘age’. A drug was considered ‘new’ when the inter-
val between the introduction of the drug (as men­
tioned in the Informatorium Medicamentorum of 
the Royal Dutch Society for the Advancement of 
Pharmacy151) and the year of publication of the 
communication was 6 years or less, and ‘estab­
lished’ when the interval was 7 or more years.
The limit of 6 years was chosen because regu­
lations in the European Union require intensified 
pharmacovigilance for 5 years after the registration 
of a drug, whereas there may be a delay of about 1 
year between the reporting of an adverse drug 
effect and the publication of the information. For 
example, the mean delay between the diagnosis of 
adverse drug reactions and their publication in 
medical journals was found to be about 63 weeks 
(for first reports).161 For drug interactions, the age 
of only one of the drugs was considered, either that 
of the acting drug or that of the affected drug.
Assessment of New Adverse Effects
Sources of Reports
With regard to sources of the reports, the topics 
were divided into 2 groups: referring only to case 
reports in The Netherlands or to reports in one or 
more additional countries.
Finally, drugs that have been removed from the 
market after the topic was published were identi­
fied. However, because of the secrecy in drug 
regulation, the question of whether the adverse 
effect had caused or contributed to withdrawal 
could not be addressed. These assessment items are 
summarised in figure 3.
Results
In the study period (1973 to 1990), a total of 
107 topics were presented in a variety of different 
publications by or in collaboration with the 
pharmacovigilance centre in The Netherlands. 
These publications contained information derived
An assessment was made of whether the adverse from original case reports (tables I to V).
effects were new or not. A topic was considered Several publications concerned more than one
‘new’ when in the publication no reference was topic and several topics were addressed in more
made to relevant information in the data sheet or than one publication. There were 81 articles or
in the literature (i.e. previously described case his- letters in national or international professional
tories). When similar cases had been published in journals. A special Adverse Reactions Bulletin
the same year, the topic was nevertheless consid- (Bulletin Bijwerkingen) was produced by the
© Adis Internationa! Limited. All rights reserved. Clin. Drug Invest. 1996 Oct; 12 (4)
Table I. Review of 107 pharmacovigilance topics
Topic summary Suspected drug Ref®
no.
ADR
type
New
topic?
No. of 
cases
Age of 
drugb
Pharmaceutical defects
Fragmentation of inhalation Cromoglycate and salbutamol 1 Yes 4° 19/18
capsules
Laboratory findings
Hyperammonaemia (in aduits) Sodium valproate 2 A Yes 4C 11
Complaints and symptoms
Cough ACE inhibitors (captopril/enalaprll) 3 A No 21° 5/1
Testicular and perineal pain Mazindol 4, nP No 8d 8
5 B No 4C 10
Diseases and syndromes
Immunoallergic hypersensitivity
Nonspecific reactions Camazepam® 6 B Yes 13c 6
(mainly rashes)
Coumarln derivatives B No 16c > 2 0
Indapamide 8 B Yes 204d 13
Mebendazole 9 B Yes 8 C 14
Placebo capsules containing quinine 10 B No 1R > 2 0
(capsulae albochin)
Terfenadine 11 B Yes 108d 3
Ticlopidlne8 12 B No 1° 3
Contact dermatitis Udder ointment (human use of 13 B No 2 C
veterinary product)
Specific hypersensitivity
Anaphylaxis and acute hypersensitivity Cinoxacin 14 B Yes 26d 5
Floctafenine 15 B No 13° 1 1
Glafenine® 16, B No 32c 9
17 nD No 116° 12
Isoflurane 18 B Yes 1c 4
Ketoconazole 19 B Yes 2c 2
Mebhydrolin 20 B Yes 3C >20
Paracetamol 21 B Yes 55d >20
Polidocanol 22 B No 3C > 20
Promethazine 23 B Yes 2C > 20
Review of reports of anaphylactic reactions; high reporting rate of glafenine® 20 B 229°
Liver
Hepatitis Diclofenac 24 B No 1 c 10
Glafenine® 25,17 B No 5C 12
Halothane 26 B No 1c 15
Ketoconazole 27 B No 5C 2
Nomifensine 28 B Yes yd 3
. Phenprocoumon 29 B No i c > 20
Pirprofen 30,31 B No 4d 5
Cholestatic hepatitis Amoxlcillin-clavulanic acid 32, B Yes 1 e 6
33 B No 5d 7
Hepatitis, serial clinicopathological studies Flutamide 34 B Yes 1e 0
Allopurinol 35 B No 6 d > 2 0
Glafenine 36,31 B No 38c 19
Ketoconazole 37,31 B No 55c 5
Nitrofurantoin/ 38,31 B No 52R 19/22
nifurtolnol
Contd
© Adis International Limited. All rights reserved. Clin. Drug Invest. 1996 Oct; 12 (4)
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Table 1. Continued
Topic summary Suspected drug Refa ADR New No. of Age of
no. type topic? cases drugb
Blood
Granulocytopenia Aprindine 39,40 B Yes 8C 2
Mianserin 41 B No 4C 4
Pirenzepine 42 B Yes 1c 3
Spironolactone 43,44 B Yes 1c >20
Ticlopidinee 12 B No 1c 3
Review of agranulocytosis reports; high reporting rate of pyrazolinone derivatives6 45,46 B - 90e
Demonstration of drug-dependent antibodies Propylthiouracil 47 B Yes 1e >20
against hematopoietic precursor cells in
agranulocytosis
Thrombocytopenia Mianserin (drug-dependent 
antibodies)
48,41 B Yes 1e 3
Nalidixic acid 49,50 B Yes 6e >20
Pirenzepine 42 B Yes 1e 3
Ticlopidine (drug-dependent 12,51 B Yes 1e 3
antibodies)e
Other organs and systems
Fever Labetolol 52,53 B Yes 2e 8
Nomifensine 28 B Yes 22d 3
Pyrazinamide 54 B No 1e >20
Pancreatitis Methyldopa 55 B No 1e 19
Parotitis Nitrofurantoin 56,57 B No 2e 13
Interstitial nephritis Cimetidine 58 B Yes 1e 3
Glafeninee 17 B No NSC 12
Sclerosing peritonitis Practolole 59,60 B No 5e 4
Photosensitivity Azapropazone 61, B No 5e 13
62 B No 190d 13
Drug toxicity (e.g. organ toxicity, hormonal effects, embryotoxicity)
Sterile meningitis Metrizamide6 63 B Yes NSC 4
Optic neuropathy Amiodarone 64 B Yes 13d 18
Ethambutol/ 65 B No 2e >20
isoniazid
Psychiatric complications (depression, anxiety, Fenfluramine 66 A No 13e >20
mania, depersonalisation; withdrawal reactions)
Peculiar visual and psychic disturbances Benzydamine® 67 A Yes 10e 6
Hallucinations in children Oxolamine® 68, A Yes 4e 12
69 A No 20d 15
Acute extrapyramidal dystonie reactions Domperldone 70, A No 9e 9
71 A No 11d 10
Psychic agitation Budesonide 72 B Yes 2e 5
Depression and dyskinesia Flunarizine 73, C Yes 8e 3
74 C No 22e 3
Psychosis, amnesia, behavioural disturbances Triazolam® 75, B Yes >100° 1
76 B No 1000e 11
Paradoxical motion sickness-like syndrome Scopolamine TTS 77,78 B Yes 3e 1
after withdrawal
Prolonged postoperative apnoea Ketamlne 79 A Yes 1e 15
Apnoea after epidural administration Sufentanil 80 A No 4e New
Sudden unexpected death in asthma patients ß2-sympathomimetic aerosols 81 C No
ocoCM ca 14
Body temperature elevation Oral contraceptives 82 A Yes 1C >20
Gynaecomastia Captopril 83 B Yes 1° 7
Interruption of menstruation Naproxen 84 A Yes 2e 6
Contd
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Table 1. Continued
Topic summary
Acute renal failure
Suspected drug
Fumarie acid-esters
Refa ADR New 
type topic?
86,87 A No
No. of 
cases
4C
Age of
drugb
Old
Oesophageal ulcers Doxycycline/ 
tetracycline capsules
88 A No 1° >20
Hyperthyroidism Kelp (Fucus vesiculosis) 85 A No 1c
Doxycycline tablets 89 A Yes 2C 16
Pinaverium bromide 90 A No 5° 2
Review of reports of oesophagus injury 91 A 57°
Nicolau syndrome (muscle and skin necrosis) Pyrazolinone derivatives0 92 B No 3° >20
Biliary concrements and colic Ceftriaxone 93,94 A Yes 2° 5
Phlebitis Ergotamine 95 A No 7° >20
Face malformations Coumarin derivatives 96,97 A No 3C >20
Spina bifida Sodium valproate 98 A No 10c 13
Drug interactions
Potentiation of coumarins Amiodarone 99,100 A No y C 12'
Azapropazone 101,102 A Yes NS° 1'
Flurbiprofen 103,104 A Yes 2C 2'
Oxolamine® 105 A Yes 2 c 5'
Cotrimoxazole 106 A No 3° 6'
Inhibition of coumarins Acetylcysteine 107 A Yes 1° 1'
Colestyramine 108 A No 5° 2'
Unexpected enzyme induction 109 A No 4° 18f
caused by barbiturates in obsolete
►
hypnotics, e.g. Bellanox®
Modifast 110 A Yes NSC 2'
Inhibition of oral contraceptives Anticonvulsants 111 A Yes 3C 120
Griseofulvin 112 A Yes 22d >209
Minocycline 113 A Yes 1c 17
Alcohol intolerance Ketoconazole 114 B No 1c 8'
Potentiation of amantadine Hydrochlorothiazide/
amiloride
115 A No 1° 8fl
Drug profile Nitrofurantoin 116 218° 13
Review of reported suspected adverse effects; no increase in reporting
Therapeutic failure
Insufficient analgesia and decreased efficacy of Buprenorphine (sublingual) 117 Yes 2° New
subsequent morphine in cancer patients
a References to the publications in this table are published in the appendix.
b Age of drug = year of publication of communication minus year of introduction, as mentioned in the Informatorium Medicamentorum 
of the Royal Dutch Society for the Advancement of Pharmacy, 
c Dutch case reports only, 
d Case reports from 2 or more countries, 
e Withdrawn from the market, 
f Age of acting drug, 
g Age of affected drug.
Abbreviations: ADR = adverse drug reaction; NS = not specified.________________________________________________________
pharmacovigilance centre in 3 volumes (1985 to cists ( ‘dear doctor letters’). 12 topics were pre- 
1987), and was distributed to all doctors and phar- sented in Tromnibus, a periodical issued by the 
macists in the country. Two articles were published Federation of Dutch Thrombosis Services.
in the Drugs Bulletin (Geneesmiddelenbulletin) In our survey, duplicate publications of topics
issued by the Ministry o f Health. Three letters were referring to the same case reports (e.g. in a foreign 
sent directly to medical practitioners and pharma- language) were not counted separately, although
Adis International Limited, All rights reserved. Clin. Drug Invest. 1996 Oct; 12 (4)
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the references are added to table I. (A few identical 
and simultaneous publications in a second journal 
were not included.) Topics that were addressed for 
a second time and contained additional informa­
tion (e.g. follow-up reports or international stud­
ies), on the other hand, were regarded as separate
Table IV. Withdrawn drugs
a Registered 6 or less years before publication of topic, 
b Registered 7 or more years before publication of topic,
Table III. Unapproved drugs in 6 topics
m m
Table II. Characteristics of 107 pharmacovigilance topics
No. of topics %
No. of case reports
1 27 25
2-10 48 45
11-50 15 14
51-100 5 5
>100 8 7
Not specified 4 4
Source of case reports
Netherlands only 92 86
Netherlands and one or more 15 14
other countries
Type of adverse effects
Type A effects 35 33
Type B effects 66 62
Type C effects 3 3
Not applicable 3 3
New or established drugs?
New drug" 42 39
Established drugb 60 56
Not applicable 5 5
New topic?
Yes 49 46
No 54 51
Not applicable 4 4
Fumaric acid esters (used In psoriasis)
Capsulae albochln Formularium Nederlandse Apothekers (FNA), 
placebo capsules containing quinine for bitter taste
Kelpasan, a kelp (Fucus vesiculosis) product containing iodine
Modifast, a slimming product containing vitamin K and sold only 
in pharmacies
Sufentanil for epidural anaesthesia (at that time not yet approved)
Veterinary udder ointment containing phenoles and citronellal 
used for self-medication in humans
Hypnotics containing barbiturates (e.g. secobarbital/ 
brallobarbital/amobarbitai in Bellanox)
Benzydamine (oral use)
Camazepam
Glafenine
Metrizamide
Nomifensine
Oxolamlne
Pirprofen
Practolol
Pyrazollnone derivatives (e.g. Baralgin, Buscopan comp, 
Butazoiidine, Irgapyrine, Tanderli, Tomanol)
Ticlopidine
Triazolam®
**■
a Triazolam was withdrawn in 1979 and reintroduced in 1990.
mmm
Table V. Pharmacotherapeutic drug categories in 107 pharmaco-
vigilance topics (more than one category per topic possible)
Category No. of %
topics
Drugs acting on the central nervous system 22 18
Anti-infective agents 20 17
Analgesic and antirheumatic drugs
1 9
16
Anticoagulants 16 13
Cardiovascular drugs 12 10
Other 32 26
The 107 topics are reviewed in table I, specify­
ing the nature of the adverse events (in summary),
drugs, references to the 
types o f adverse effects, numbers of case reports,
‘age’ of the drugs, and whether or not 
were new. 66 (62%) topics were classified as type 
B effects and 35 (33%) as type A effects, including 
13 of the 14 drug interactions, 
cerned type C effects (3%). Three topics did not 
refer to an adverse effect, but to a pharmaceutical 
defect, a therapeutic failure and a drug review,
Seventy-five (70%) of the 107 topics referred 
to 10 or less case reports, including single cases in 
27 topics (table II). In 15 (14%) topics the number 
of case reports was between 11 and 50, whereas in
© Adis International Limited. All rights reserved. Clin. Drug Invest. 1996 Oct; 12 (4)
214 Mt’i/boom et al.
13 (12%) topics more than 50 case reports were There were different types of publications:
involved. In 4 topics the numbers of cases were not warning letters, brief communications, original 
precisely specified. 42 (39%) topics concerned journal articles, or additions to articles by others.
new m edicines, whereas 60 (57%) referred to As table I shows, there was a remarkable pluri-
established products. 49 (46%) topics were consid- formity of topics encountered in pharmaco-
ered new; 54 (51%) had been described previously. vigilance in The Netherlands, illustrating the
In the reviews of anaphylactic reactions, agranulo- diversity and heterogeneity of adverse drug effects,
cytosis and oesophageal injury, the question of At the same time, however, there appeared to be a
whether drug and topic were new was not ad- predominance of concrete, characteristic and often
dressed; in the review of nitrofurantoin, the latter serious diseases, notably specific hypersensitivity
question only was thought not to be relevant. reactions (n = 46; 43%), e.g. anaphylaxis (n = 11; 
Furthermore, for 2 unapproved drugs the age 10%), blood dyscrasias (n = 11; 10%) and liver 
question was considered inappropriate. injury (n = 14; 13%)) toxic manifestations or syn-
In 92 (86%) topics the data were limited to dromes (n = 32; 30%) -  especially involving the 
Dutch case histories; 15 (14%) case reports from
one or more other countries were also included.
The reviews of anaphylactic reactions, agranulo­
cytosis and oesophageal injury referred to many
different drugs and are not included in this figure. 
72 different approved drugs or drug groups and 6 
unofficial drugs were involved in the topics (tables 
I and III). Of the 72 approved drugs, 12 (17%) have 
been withdrawn from the market (table IV). The 5 
pharmacotherapeutic drug groups most frequently 
involved are listed in table V.
nervous system (n = 17; 16%), and drug interac­
tions (n = 14; 13%); altogether 86% of topics. This 
pattern resembles that in the study of drug with­
drawals by Spriet-Pourra and AuricheJ71 In that 
study, of 66 products withdrawn because of clin­
ical adverse effects, 14 (21 %) were associated with 
liver injury, 12 (18%) with blood dyscrasias, and 9 
(14%) with neurological disorders, together ac­
counting for 33 (50%) withdrawals.
The majority o f topics (62%) concerned type B 
adverse effects. This is likely to reflect the situation
that type B effects are a primary concern of
Discussion pharmacovigilance in the first place. However, 
type A adverse effects occur with relatively high
From the start, the use of data reported to The 
Netherlands pharmacovigilance centre in publica­
tions has been limited by confidentiality and uncer­
tainty with regard to the role of the suspected drugs. 
During the study period there was, however, an ob­
vious tendency to use the data to their best advan­
tage in publications for the medical/pharmaceuti­
cal community. The choice of the topics was 
influenced by the interests and concerns of the 
pharmacovigilance centre and its Advisory Com­
mittee. Case reports may attract attention for sev-
frequency and in great variety, and this finding also 
suggests that spontaneous reporting is especially 
effective in detecting type B effects. Of the 35 
topics classified as type A effects, 13 were drug 
interactions. The 9 interactions with coumarin de­
rivatives were reported with the aid of a reporting 
project in collaboration with the countrywide or­
ganisation of 69 regional outpatient anticoagulant 
monitoring centres (Dutch Federation of Thrombo­
sis Services).*8!
Only 3 topics were considered to relate to type
eral reasons, e.g. because the drug is new, the ad- C effects. Depression and parkinsonism in associ-
verse event is unexpected, serious or little known, ation with flunarizine were categorised as type C
or because of the scientific value of the data. In effects because o f the possibility of coincidence
other cases a request for information from outside (2 different publications). The inquiry on sudden
(e.g. someone preparing an article) may lead to the and unexpected death during the use of {i^-sympa-
inclusion of case reports in a publication. thomimetic aerosols (the other type C effect) was
<0 Adis International Limited. All rights reserved. Clin, Drug Invest. 1996 Oct; 12 (4)
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performed after receiving a few spontaneous case An interesting finding was that many o f  the
reports. The results confirmed the existence of the pharmacovigilance topics referred to fairly sm all 
association, but a cause-effect relationship re- numbers of case reports (table II). In 70% o f  the
mained uncertain. topics, 10 or fewer case reports were involved. In
In the light of the historical thalidomide tragedy, the 49 topics classified as new, a similar pattern 
it is worth mentioning that 2 topics (2%) concerned was found: in 37 (76%) the number of case reports 
congenital malformations (coumarins and valproic was 10 or fewer. This is in accordance with a recent
Mebhydrolin study in the UK. Of 46 problems naming one drug
the many associations in the review of anaphylac- and one serious (type of) reaction, published in
tic reactions, was included as a separate topic be- Current Problems, 24 (52%) were concerned
cause it had not been published previously. For one 10 or fewer yellow card reports, and of these 12
drug (nitrofurantoin), a profile o f the reported sus- (26%) with only 4 or fewer cases.191 These findings
pected adverse effects was included in a review are in keeping with the view of the WHO Collab-
article. orating Centre for International Drug Monitoring
One single topic referred to a pharmaceutical that in the signalling of type B adverse effects, a 
defect, i.e. fragmentation during administration of minimum of some 3 to 9 case reports is o ften
capsules containing powder for inhalation (cromo- needed.110,111
glycate or salbutamol). Therapeutic failure was The situation that there is a minimal number of
reported only once (buprenorphine in cancer reports needed to provide sufficient evidence for 
patients), but it should be added that in the 7 topics the detection of an adverse effect suggests that the
on inhibition of oral contraceptives or coumarins, time needed for detection is directly dependent
lack of effect was of course the major issue. There upon the rate of reporting. The smaller the propor
were no unexpected therapeutic effects. tion of doctors reporting, the smaller the monitored
With regard to suspected drug involvement, it population of drug users, and the longer it takes  
is noteworthy that there was a predominance of before the required minimal number o f adverse re­
established (56%) over new drugs (39%) [‘not ap- action patients have accumulated.
propriate’ in 5%]. Of the 49 topics classified as In 13 topics, on the other hand, more than
new, 20 (41%) concerned established drugs. 50 case reports were involved. Two of these w ere
These findings emphasise that pharmacovigilance serial studies o f c lin icopathological patterns:
should not be restricted to new medicines only. It hepatic injury with ketoconazole and nitrofurantoin,
also shows the relativity o f the rule recently intro- respectively. Only in these 2 studies was an estim -
duced in the European Union, that 5 years after ation of the frequency of the adverse effect m ade,
registration of a medicine pharmacovigilance is For 5 other drugs the numbers o f reports w ere
considerably relaxed. thought to reflect relatively frequent ad verse
Less than half of the topics (46%)) were consid- reactions, w ithout further sp ec if ica tio n , i .e .
ered new. Many more topics, however, had an ob- azapropazone (photosensitivity), glafenine (ana-
vious news value, e.g. because the adverse effects phylactic reactions), indapamide (rashes), pyrazo-
were only recently detected or were little known in linone derivatives (agranulocytosis), and triazolam
the medical community. Original observations (psychic disturbances).
concerning adverse effects that have only once or Triazolam (which received an unusually large
twice been reported in the distant past may be of number o f reports in 1979), was a special case that
considerable value. In addition, the various review has been reviewed in detail elsewhere.1121
articles and clinicopathological studies, although In the review article on nitrofurantoin it was
not classified as new topics, presented many new concluded that there were no indications for an in-
pieces of information. crease in reporting, relative to the consumption o f
© Adis International Limited, All rights reserved. Clin. Drug Invest. 1996 Oct.- 12 (4)
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the drug. Four of the topics referring to more than 3. A limited number of adverse effects are re-
50 case reports were cumulative international sponsible for the majority of the more serious 
studies (i.e. on azapropazone, indapamide, paracet- problems encountered in pharmacovigilance. 
amol and terfenadine).
Five pharmacotherapeutic groups accounted for 
a total of 74% of the topics: drugs acting on the 
central nervous system, anti-infective agents, anal­
gesic and antirheumatic drugs, anticoagulants, and 
cardiovascular drugs (table V). Many of these 
drugs are known causes of relatively frequent 
and/or serious adverse effects. The emergence of 
anticoagulants to some extent reflects the above- 
mentioned special interaction reporting project. 
The absence of cytotoxic drugs, on the other hand, 
undoubtedly reflects selective under-reporting.
The majority o f topics (n = 101; 94%) con­
cerned approved drugs. In addition, 2 topics con-
Pharmacovigilance may be improved by intensi­
fied monitoring of these effects.
4. Information derived from only small numbers 
of case reports may already provide valuable infor­
mation and lead to the detection of new
5. The provision of first reports (i.e. on new ad­
verse effects) is a major role of pharmacovigilance.
6. In addition, the dissemination to healthcare 
practitioners of all sorts of information relevant to 
the knowledge of adverse effects and the appro­
priate use of medicines (including reminders of 
previously reported adverse effects) is an impor-
cerned unapproved remedies, one topic concerned tant function of pharmacovigilance.
the human use of a veterinary product, one in- 7. Pharmacovigilance should cover all drugs on
volved a warning for the presence of quinine in a the market, new and established, approved and 
placebo (capsulae albochin), one concerned the un- nonorthodox.
approved use of a registered drug, and one referred 8. Pharmacovigilance topics often concern pre-
to a pharmacy-only slimming product interacting dominantly qualitative information. For precise
with coumarin anticoagulants (table III).
Clinical Implications
Pharmacovigilance is a complex process of data 
collection, assessment and distribution, aiming at 
the safe use of medicines and the prevention of 
adverse effects. A better understanding of the 
mechanisms and procedures involved and their
quantitative information (e.g. frequency), addi­
tional studies are often needed.
9. Signal detection speed is directly dependent 
on the size of the monitored population of drug 
users and therefore on the proportion of doctors 
contributing to the reporting system. Under-report­
ing delays the detection of rare adverse effects. In 
addition, the capacity of spontaneous reporting to
scientific, logistic and educational aspects may en- provide clues with regard to the frequency of ad- 
able further improvements. The experiences with verse effects (important for regulatory decision
pharmacovigilance in The Netherlands lend sup­
port to the following observations:
1. Pharmacovigilance must continuously hold 
an open mind for the new, the unusual and the un­
expected. The routines involved should enable the 
precise recording of case histories and not lead to 
simplification or distortion of adverse events.
2. Spontaneous reporting is particularly useful 
in the detection of type B adverse effects and of 
type A effects that were not identified during clin­
ical testing (including drug interactions), but is of 
less value in the study of type C effects.
making) also depends on the proportion of report­
ing doctors.
10. The integration of national and international
igilance may require further
ment.
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